Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has informed the stock exchanges that a meeting of its Board of Directors is scheduled for Tuesday, July 29, 2025, at the registered office. The main agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (Q1 FY26). The filing was made under SEBI Listing Regulations (Regulation 29). The company's trading window for designated persons and their immediate relatives has been closed since July 1, 2025, and will remain closed until 48 hours after the results are announced.
This is a routine regulatory intimation ahead of the Q1 FY26 earnings announcement. Investors should watch for the actual results on July 29, 2025, to assess the company's quarterly performance. The stock may see some activity around the results date due to the trading window closure.